Palazzo et al. [12] performed multivariate analyses on subgroups of lanreotide-treated patients with malignant digestive NETs, which revealed significant associations between PFS and patients with a proliferation index (Ki-67) of ≤5% (p = 0.009), pre-treatment tumour stability (p = 0.008), or hepatic tumour load of ≤25% (p = 0.004). This evidence concerns the gene MKI67 and neoplasm.